251 related articles for article (PubMed ID: 9382363)
1. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.
Bennett WG; Inoue Y; Beck JR; Wong JB; Pauker SG; Davis GL
Ann Intern Med; 1997 Nov; 127(10):855-65. PubMed ID: 9382363
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
Wong JB; Bennett WG; Koff RS; Pauker SG
JAMA; 1998 Dec 23-30; 280(24):2088-93. PubMed ID: 9875876
[TBL] [Abstract][Full Text] [Related]
3. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis.
Davis GL; Beck JR; Farrell G; Poynard T
J Viral Hepat; 1998 Sep; 5(5):313-21. PubMed ID: 9795915
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U; Sroczynski G; Rossol S; Wasem J; Ravens-Sieberer U; Kurth BM; Manns MP; McHutchison JG; Wong JB; ;
Gut; 2003 Mar; 52(3):425-32. PubMed ID: 12584228
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
Wong JB; Koff RS; Tinè F; Pauker SG
Ann Intern Med; 1995 May; 122(9):664-75. PubMed ID: 7702228
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N
Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
Grieve R; Roberts J; Wright M; Sweeting M; DeAngelis D; Rosenberg W; Bassendine M; Main J; Thomas H
Gut; 2006 Sep; 55(9):1332-8. PubMed ID: 15994216
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Wong JB; Davis GL; Pauker SG
Am J Med; 2000 Apr; 108(5):366-73. PubMed ID: 10759092
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.
Kim WR; Poterucha JJ; Hermans JE; Therneau TM; Dickson ER; Evans RW; Gross JB
Ann Intern Med; 1997 Nov; 127(10):866-74. PubMed ID: 9382364
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.
Buti M; Medina M; Casado MA; Wong JB; Fosbrook L; Esteban R
Aliment Pharmacol Ther; 2003 Mar; 17(5):687-94. PubMed ID: 12641518
[TBL] [Abstract][Full Text] [Related]
19. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness.
Wong JB
Acta Gastroenterol Belg; 1998; 61(2):238-42. PubMed ID: 9658620
[TBL] [Abstract][Full Text] [Related]
20. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]